EP0017 / Ellipses Pharma, SunRock Biopharma - LARVOL DELTA

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein (Businesswire) - "SunRock Biopharma S.L...and Ellipses Pharma Limited...announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound. In line with its strategy, Ellipses intends to out licence EP0017 for commercialisation if it proves safe and effective in clinical trials. SunRock will continue to be involved in the development of EP0017 to ensure efficient translational activities through a service agreement with Ellipses.If Ellipses out-licences EP0017, SunRock will also receive milestone payments and royalties."

Licensing / partnership • Oncology